The HDE trades effectiveness for probable benefit

A device file that treats a Humanitarian Device Exemption as a smaller PMA — the same reasonable-assurance-of-effectiveness standard, just for a rarer disease — has misread what section 520(m) of the FD&C Act actually waives. An HDE, governed by 21 CFR Part 814 Subpart H, doesn't ask a sponsor to clear a scaled-down version of the effectiveness bar every other PMA has to clear. It removes that bar entirely, on purpose, and substitutes a different question: does the probable benefit to health from the device outweigh the risk of injury or illness from using it. That's not a rounding difference in how strict the review runs. It's a different regulatory instrument, built for a population too small to generate the evidence a normal PMA would demand.

What 520(m) actually waives

Section 814.100(a) states the purpose directly: Subpart H exists to encourage the discovery and use of devices for diseases or conditions that affect or are manifested in not more than 8,000 individuals in the United States per year, and it provides a path to marketing approval notwithstanding the absence of reasonable assurance of effectiveness that sections 514 and 515 of the Act would otherwise require. The word notwithstanding is doing real work there. An HDE application still has to satisfy 814.104(b)(4): an explanation of why the probable benefit to health from the device outweighs the risk of injury or illness, weighed against the probable risks and benefits of currently available devices or alternative treatments. That's a real evidentiary showing, built from whatever clinical experience or investigational data the applicant can reasonably obtain — it just isn't the same showing a PMA reviewer is checking a submission against.

The population threshold is the gate, and it moved

The 8,000-person figure isn't the original number. Section 3052 of the 21st Century Cures Act, enacted December 13, 2016, raised the Humanitarian Use Device threshold from fewer than 4,000 individuals to not more than 8,000, and FDA's technical amendment codifying the new figure in the CFR published June 7, 2017. A designation memo or regulatory strategy deck still citing the 4,000-person ceiling is citing a threshold Congress replaced years ago — and a device serving a population between 4,000 and 8,000 people that was screened out under the old number deserves a second look under the current one.

Profit is allowed more often than the reputation suggests

HDEs carry a longstanding reputation as non-profit instruments, and that reputation is now narrower than the rule. Section 520(m)(6)(A) allows an HDE holder to sell for profit where the disease or condition occurs in a pediatric population and the device is labeled for that use, or where the disease or condition occurs in adults and doesn't occur in pediatric patients — or occurs in pediatric patients in numbers too small to make pediatric device development practical or safe. Between those two branches, most HDE-eligible conditions clear one of them; the real exclusion is narrower than “pediatric only” and catches mainly a condition that occurs meaningfully in both adults and children where the device isn't labeled for the pediatric case. Where profit is allowed, FDA sets an Annual Distribution Number capping the units sold — calculated as the number of devices one patient needs per year, multiplied by 8,000. A file that assumes profit is off the table without checking which branch the device's condition falls under is leaving a real commercial question unasked.

The IRB requirement doesn't relax because the effectiveness bar did

Removing the effectiveness requirement doesn't remove oversight at the point of use. Section 814.124(a) requires that a HUD be administered only in facilities under the oversight of an IRB constituted under 21 CFR Part 56, including continuing review of the device's use, and only where that specific use has been approved by an IRB. Every facility administering the device carries its own IRB approval and its own continuing-review obligation — a national HDE approval from FDA doesn't substitute for the site-level IRB approval each hospital or clinic still has to obtain and maintain.

Not a shortcut through Breakthrough or De Novo

Breakthrough designation buys faster, more interactive review across whatever pathway a device is actually pursuing — it isn't a marketing authorization by itself, and an HDE isn't a consolation prize for a device that couldn't clear it. De Novo trades a predicate for FDA's own benefit-risk finding on a novel device, but it still asks for the same reasonable-assurance standard a 510(k) or PMA would use for its risk class. An HDE is the only one of the three that waives the effectiveness standard outright, and it does that specifically because the population is too small to power the evidence effectiveness would require — not because the device or the sponsor's evidence file is somehow weaker.

Where this meets the file

An HDE tracking file needs the population estimate and its citation, the probable-benefit rationale distinct from an effectiveness argument, a profit-eligibility determination under 520(m)(6) with the ADN calculation where it applies, and a per-facility log of IRB approval and continuing-review dates — four fields a PMA tracker never needs and an HDE file can't skip. If your program tracks HDE eligibility or profit status differently, the shelf takes that correction directly, and an HDE eligibility worksheet built around 814.104's own probable-benefit standard is previewed in the launch catalog.